Patents by Inventor Sandra Luettgau

Sandra Luettgau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding molecules, especially antibodies, binding to L1CAM (CD171)
    Patent number: 10400037
    Abstract: The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: September 3, 2019
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Peter Altevogt, Sandra Lüttgau, Gerhard Moldenhauer, John Hazin
  • BINDING MOLECULES, ESPECIALLY ANTIBODIES, BINDING TO L1CAM (CD171)
    Publication number: 20170306015
    Abstract: The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.
    Type: Application
    Filed: September 28, 2015
    Publication date: October 26, 2017
    Inventors: Peter ALTEVOGT, Sandra LÜTTGAU, Gerhard MOLDENHAUER, John HAZIN
  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 9260521
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 16, 2016
    Assignees: MEDIGENE AG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTS
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • Method for producing protein libraries and for selecting proteins from said libraries
    Patent number: 8771960
    Abstract: The invention relates to a method for the production of a protein library, in particular an antibody library, which is highly diverse and for the selection of proteins, in particular antibodies, therefrom.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 8, 2014
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Frank Breitling, Gerhard Moldenhauer, Annemarie Poustka, Thorsten Kühlwein, Sandra Lüttgau
  • TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY
    Publication number: 20140120117
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 1, 2014
    Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 8580258
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: November 12, 2013
    Assignees: Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AG
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY
    Publication number: 20120258039
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Application
    Filed: February 6, 2012
    Publication date: October 11, 2012
    Inventors: Daniela Gast, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Wolterink, Sandra Lüttgau, Ulrich Mõbius, Yi Li
  • Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer
    Publication number: 20120213805
    Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer.
    Type: Application
    Filed: April 8, 2010
    Publication date: August 23, 2012
    Inventors: Heinz Faulstich, Frank Breitling, Sandra Lüttgau, Gerhard Moldenhauer
  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 8138313
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: March 20, 2012
    Assignees: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts, MediGene AG
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Bärreiter, Sandra Lüttgau, Ulrich Möbius, Yi Li